亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        Role of gut microbiota in primary biliary cholangitis

        2022-03-03 10:39:34WuMengJinSiYueSongXiaoFenXuChengPingWenChangFengHu

        Wu-Meng Jin, Si-Yue Song, Xiao-Fen Xu, Cheng-Ping Wen, Chang-Feng Hu

        College of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China

        Primary biliary cholangitis (PBC, formerly known as primary biliary cirrhosis) is a chronic female-predominant inflammatory and cholestatic liver disease with a prolonged course and poor prognosis [1] . It is characterized by anti-mitochondrial autoantibody (AMA), immunoglobulin M and lymphocyte infiltration in the portal area of liver tissue. A recent systemic review has shown a steady rise both in incidence and prevalence of PBC, with 5.31/10 0 0 0 0 persons and 40.2/10 0 0 0 0 persons, respectively [2] .It can cause fatigue, pruritus and is associated with a high risk of cirrhosis and liver failure if left untreated [3] . The pathogenesis of PBC may be related to genetic, environmental, immune factors and individual susceptibility, but the specific etiology is not clear.Several previous studies [ 4 , 5 ] have found that gut microbiota plays an important role in a variety of liver diseases, including PBC. The bidirectional crosstalk between liver and microbiome appears to be crucial in maintaining health and could be therapeutically targeted,such as by fecal microbiota transplantation.

        A series of basic and clinical studies have shown the association between intestinal microbiota and cholestatic liver diseases. In early-stage PBC patients, the gut was depleted of some potentially beneficial bacteria but enriched in some bacterial taxa containing opportunistic pathogens [6] . Furthermore, an epidemiological study has identified that the exposure to urinary tract infection in susceptible host, predominantly byEscherichiacoli, is one of the risk factors for PBC [7] . As known, the gut microbiota generally influences the host immunity, and the immune system also regulates the microbiota by protecting the integrity of the intestinal barrier and immunological rejection in turn [8] . Dysregulation of the gut microbiota might act as a critical factor in the progress of the diseases. A recent clinical research has disclosed a comprehensive signature of gut microbiota in PBC and reported that gut microbiome dysbiosis could be partially ameliorated after ursodeoxycholic acid(UDCA) treatment (which is the first-line treatment of PBC and effective in preventing disease progression in about two thirds of the patients) [9] . Another basic study [10] has taken advantage of a well-characterized murine model of PBC to investigate the influences of gut microbiota on autoimmune cholangitis. As noted,intestinal microbiome disturbances cause cholangitis in mice and the altered composition of gut microbiota by administration of antibiotics significantly alleviates T-cell-mediated infiltration and bile duct damage. Therefore, gut microbiota could break the immune homeostasis and thus directly involved in the pathogenesis of PBC.

        However, it is not clear whether the altered gut microbiome is a trigger for PBC or simply a reflection of the disease status.Hence, there are several mechanisms regarding the immunological impact on gut microbiota in the diseases [11] . It is known that the dominant autoepitope of PBC is the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2) of the mitochondria, which is recognized by the AMA [12] . Interestingly, recent data have shown that the gram-negative bacteria, such asEscherichiacoli,HelicobacterandSphingomonas, in the gut microbial community of susceptible hosts have the relevant protein closely resembling the PDC-E2 [ 13 , 14 ]. Subsequently, the enterohepatic circulation transports the potential microbes or metabolites of gut microbiota from the gut to liver through the portal venous system. In this process,dominant epitopes recognized by the immune cells induce extensive cross-reactivity between autoepitopes and microbial mimics through the mechanism of molecular mimicry, playing a role in the induction of AMA [15] . Indeed, several studies have revealed that AMA in the serum from PBC patients could react with bacterium sequences [16–18] . One study has discovered that 97.5% AMApositive patients with PBC have serum reactivity against the three definedSphingomonasproteins [17] . Another study revealed the interaction between AMA and protein components ofEscherichia coliisolated from stool specimens of PBC patients, suggesting that the bacteria may promote the disease progression by initiating immune damage patterns in susceptible hosts [18] . Furthermore, the dysbiosis of gut microbiota impairs the mucosal immune system.The aberrant activation of T cells, specific chemokine receptors and integrins expressed in mucosal lymphocytes are abnormally recruited from the gut into the liver, triggering autoimmune responses upon recognition of the antigens [19] . As aforementioned,compositional and functional alterations in the microbiota are crucial regulators in the potential involvement of gut lymphocyte homing.

        Apart from direct interaction with the immune system in gutliver axis, bile acids, the end products of hepatic cholesterol metabolism, are also one of the important mediators of the gutliver crosstalk. As pleiotropic signaling molecules, bile acids interact with gut microbiota through the signaling pathway mediated by bile acid receptors, such as transmembrane G-protein-coupled receptor 5 (TGR5) and farnesoid X-activated receptor (FXR) expressed in the liver including the biliary tree as well as in the intestinal epithelial cells [20] . Recent data highlight the role of bile acids-activated TGR5 as a major inhibitor of cytokine expression and secretion, thereby further reducing biliary and intestinal inflammation [21] . Additional data suggest that the activation of the nuclear receptor FXR transcription in intestine protects the liver from cirrhosis in mice by regulating the hepatic bile acids synthesis [22] . Notably, bile acids are synthesized in the liver via both classical and alternative pathways involving more than 17 different enzymes, including the rate-limiting enzyme cholesterol 7α-hydroxylase (CYP7A1), which is down-regulated by gut microbiota and in turn, attenuates the activity of classical pathway.On the one hand, perturbations of microbiota and their metabolites exert a profound influence on bile acid pool and modulate the activity of bile acids-activated receptors. On the other hand, bile acids have direct antibacterial effects by inhibiting the growth of certain bile sensitive bacteria and affect microbiota indirectly via nuclear receptors [23] . It is noteworthy that bile acids have effects on both bacterial membrane and intestinal mucosa. Furthermore, there is evidence that bile acids may alter critical proteins in microbiota through unfolding, aggregation and disulfide stress, thereby altering their biological functions.As the disease progresses, bile secretion and transport are impaired, with the weakened function of bile acids, leading to further intestinal microbiota disorders. In general, bacteria tend to overgrow and translocate in the small intestine causing a series of subsequent detrimental effects due to biliary obstruction. Collectively, the interaction between gut microbiota and bile acids is bidirectional, associated with the initiation and progression of PBC.

        By altering the bile acid pool in PBC patients, it is possible to correct a part of gut microbiota dysregulation and reduce bile duct damage caused by cholestasis. As already mentioned, UDCA is well recognized as the first-line treatment for PBC that can effectively improve patients’ survival and significantly decrease the risk of severe complications. However, some patients have poor improvement after taking the drugs. Currently, regulation of gut microbiota is expected to be a potential therapeutic target for PBC. Fecal microbiota transplantation, as an innovative clinical therapy, can improve the composition and function of gut microbiota in recipients via introducing the specially treated fecal suspension from healthy donors into the intestines of patients. A study [24] performed microbiota transplantation in 10 patients with cholestatic liver disease to restore the disrupted microbiota and ameliorate bacterial imbalances. Overall, the bacterial diversity improved in all patients after fecal microbiota transplantation in early week and alkaline phosphatase levels decreased in 30% patients. Another phase I clinical safety trial also has found that the patients with decompensated cirrhosis could restore metabolic capability after fecal microbiota transplantation by inducing the secretion of short-chain fatty acids and modulating bile acid profiles, especially in the shortterm after treatment [25] . Therefore, regulation of gut microbiota by prebiotics, probiotics or small molecules with therapeutic benefits harvested from the microbiota may be the new tools for PBC.

        In summary, gut microbiota plays a considerable role in the progression of PBC by regulating enterohepatic circulation and immune responses. They are able to alter bile acid pool, and in turn, bile acids can shape the gut microbiota community. There is still much remained to be discovered about the specific mechanisms between microbiota, bile acids and PBC. In order to carry out fecal microbiota transplantation precisely, accurate identification and quantitative analysis of gut microbiota should be the primary step to develop a new therapeutic approach. Therefore, future safety and efficacy trials are required to better refine the underlying mechanisms of prebiotics, probiotics and fecal microbiota transplantation in order to explore the role of microbiota as diagnostic and prognostic tools.

        Acknowledgments

        None.

        CRediT authorship contribution statement

        Wu-Meng Jin: Data curation, Investigation, Writing - original draft. Si-Yue Song: Investigation, Writing - review & editing. Xiao-Fen Xu: Investigation, Writing - review & editing. Cheng-Ping Wen: Conceptualization, Writing - review & editing. Chang-Feng Hu: Conceptualization, Funding acquisition, Writing - review &editing.

        Funding

        The study was partially supported by a grant from the Natural Science Foundation of Zhejiang Province ( LY20B050 0 06 ).

        Ethical approval

        Not needed.

        Competing interest

        No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

        毛片在线播放亚洲免费中文网| 国产成人精品自在线无码| 国产亚洲欧美另类久久久| 男生自撸视频在线观看| 亚洲欧洲日产国码av系列天堂| 亚洲av日韩综合一区在线观看| 国产精品青草视频免费播放| 又爽又猛又大又湿的视频| 日韩精品专区在线观看| 四虎影视永久在线观看| 欧美日韩国产一区二区三区地区| 97中文字幕一区二区| 久久天堂精品一区二区三区四区| 天堂资源中文最新版在线一区| 亚洲国产一区在线二区三区| 精品专区一区二区三区| 日韩午夜理论免费tv影院| 中文字幕一区在线观看视频| 国产精品亚洲片夜色在线| 国产在线视频一区二区三| 中文亚洲av片不卡在线观看| 7777精品伊人久久久大香线蕉| 国产精品原创永久在线观看| 久久亚洲免费精品视频| 中文字幕人妻第一区| 精品久久久久久久久免费午夜福利| 久久伊人网久久伊人网| 国产亚洲一区二区三区| 台湾无码av一区二区三区| 色系免费一区二区三区| 日本岛国一区二区三区四区| 国产伦人人人人人人性| 999国产精品亚洲77777| 久久无人码人妻一区二区三区| 国产情侣一区二区| 亚洲av无码国产剧情| av大片在线无码永久免费网址| 91精品人妻一区二区三区久久久| 午夜成人鲁丝片午夜精品 | 在线涩涩免费观看国产精品 | 日躁夜躁狠狠躁2001|